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Introduction
As the health care system moves further toward enhanced
patient empowerment, many members of the general popula-
tion are seeking medical answers for themselves in their
genome. Direct-to-consumer (DTC) companies offer genetic
testing that promises to establish ancestry and predisposition
to traits, diseases and conditions (Harris et al. 2013). DTC
companies predominately offer panel-based testing, which
interrogates single nucleotide polymorphisms (SNPs) in or
near specific genes. Some panels target ancestry; others target
SNPs that have been associated statistically with disease. The
true predictive value of panels that incorporate numerous
SNPS into mathematical risk modeling is unknown, particu-
larly when considering the small proportion of the overall
heritability of a trait that is accounted for by these genetic
variants (McCarthy et al. 2008). Perhaps in response to this
and to concerns articulated by regulatory authorities, some
companies have left the DTC medical testing market (Kalf
et al. 2014). Other companies are looking to expand their
services to more comprehensive genetic testing, such as whole
exome sequencing (WES).
Although high-throughput genetic testing such as whole
exome sequencing and whole genome sequencing (WGS) are
typically offered only upon the request of a physician who is
caring for the patient (Yang et al. 2013), we were recently
consulted by a woman who had had WES performed by
23andMe on a private-pay, direct-to-consumer basis as part
of the company’s own in-house research protocol (the Exome
80X Pilot Program). Results of physician-ordered WES and
WGS are returned to the requesting physician with an inter-
pretation from the lab, though the physician must use his or
her own professional judgment inmaking the final decision on
whether to act on any variants flagged as “actionable” by the
testing laboratory (Sturm and Manickam 2012). This woman
first consulted us at a time when she had access to her raw
data, but had not yet received the research report from
23andMe. Subsequent to our analysis, she did receive a report
that flagged some (but not all) of the variants that we had
identified, and listed several rare variants in other genes of
medical interest. Thus, we had the opportunity to interpret
what we considered medically actionable in her exome and
compare our own results to those of the company, which the
consultand provided to us after we had completed our own
research-based analysis and Sanger validation studies.
To our knowledge,WES is still new to the DTCmarket and
not yet widely available. Although the coding exome repre-
sents only 1 % of the genome, it is the best-understood part of
the genome and is believed to contain 85% of disease-causing
variants (Choi et al. 2009). WES has the potential to be more
informative than panels, specifically because of the inclusion
of rare DNA variants that would have a higher allele-specific
effect size (and thus higher predictive value for disease).
However, the information generated by WES is difficult and
time-consuming to interpret due to its sheer volume and
complexity (Dewey et al. 2014). Furthermore, Variants of
Uncertain Significance (VUS - genetic variants not previously
identified or on which there is little population or functional
data) are found in every clinical and research exome. Thus,
any detailed WES report is likely to contain several rare
variants that may be disease-causing in the heterozygous state
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(dominant pathogenic variants), may be disease-causing in the
homozygous or compound heterozygous state (recessive path-
ogenic variants), or may be disease-causing in the hemizygous
state (X-linked recessive pathogenic variants) as well as those
that are rare but may not be causative of disease at all (truly
benign variants). There are also likely to be many rare variants
that modify disease risk to a small extent, but due to the low
power of any study to quantify the effect of a rare, mildly
deleterious allele, these will not be discussed explicitly here.
An important ethical challenge when sequencing the ex-
ome is the possibility of “incidental findings” – sometimes
defined as actionable variants discovered as a result of genetic
testing that are unrelated to the original reason for the test
(Lohn et al. 2013). The ACMG recently published (Green
et al. 2013) and clarified (ACMG 2013) recommendations for
reporting such findings, suggesting that clinical laboratories
have the ethical responsibility to look for and report variants in
57 genes that have been associated confidently with disease.
Though these best-practice guidelines would apply to certified
medical testing labs, they do not apply explicitly to research
testing, or to DTCWES testing that is not licensed as a clinical
test. Nonetheless, these guidelines do provide the closest
approximation of a consensus within the field regarding best
practices in reporting, when confronted by one or more inci-
dental findings.
The “early adopters” of DTC genetic testing have been
reported to be relatively well-educated and to have high
confidence in their ability to navigate the health care system
and to understand genetics (Gollust et al. 2012; McBride et al.
2009). They tend to be concerned about their risk of a partic-
ular disease, or motivated more by curiosity. Early adopters
often turn to healthcare professionals, such as physicians, to
help them interpret the results and/or for clinical action (such
as further follow up or health interventions) in response to the
genetic testing report (Gollust et al. 2012).
When faced with a patient requesting interpretation and
additional clinical tests based on a DTC company’s genetic
testing report, many healthcare professionals are uncertain
regarding the specifics of their fiduciary duty. Primary care
practitioners may not possess the knowledge to interpret the
results fully, nor to make a clinical decision based on the
reports. In a study of genetic counselors and clinical geneti-
cists in Australia, it was found that only 7 % were confident in
their ability to interpret and explain DTC genetic testing
results (Brett et al. 2012). While the study included SNP
panels, whole genome and exome sequencing as well as
single-gene sequencing, it is clear healthcare professionals
are unprepared for patients wishing to discuss their results.
Furthermore, because the predictive power of these test results
is often not as strong as the DTC reports suggest (Wade and
Wilfond 2006), the effectiveness (i.e. clinical utility) of inter-
ventions based upon DTC genetic results has not yet been
established. This uncertainty places genetic counselors and
other healthcare professionals in a difficult position. Should
they interpret the results, and if so, how do they know when
they have extracted all relevant information from the report?
How far into the primary literature must they go to interpret a
panel-based test, and must they provide a specific interpreta-
tion for each rare variant, if such a list is also provided?
The following case study describes the journey of an indi-
vidual womanwho sought exome sequencing on a DTC basis,
and then sought subsequent data analysis and interpretation.
We discuss the challenges of interpreting exome data in the
context of a complicated medical history of common, com-
plex disease, and of providing genetic counseling on rare
variants to such individuals. The patient provided written
informed consent for her personal data to be interpreted on a
research basis, and for her case to be presented in this journal.
Case History
Medical History
The individual is of Sinhalese descent and is currently 53 years
of age, with a Bachelor’s degree from a major Canadian
university. She recalls that her medical problems began when
she was approximately 26 years old. She was prescribed
flutamide in her early 30s for hirsutism. While on it, she
experienced unusual personality changes and a drastic loss
of hand-eye coordination. After 6 months of treatment, she
stopped the drug and the personality changes resolved.
However, she does not believe her hand-eye coordination
recovered fully. Subsequently, she has experienced additional
adverse drug reactions to multiple medications, including
adverse reactions to drugs she had previously tolerated well
such as statins.
She did not recall the exact age at which she was diagnosed
with polycystic ovarian syndrome, but had a right ovarian
cystectomy her early 40s, and 2–3 years later, a full hysterec-
tomy and right oophorectomy for menorrhagia. She had also
been followed for anxiety, thought to be related to a difficult
childhood. She stated that she had been found to have elevated
testosterone levels and decreased estrogen and progesterone
levels since her oophorectomy, though primary documenta-
tion was not available. She had been diagnosed with hyper-
lipidemia in her early 30s, and mild type I von Willebrand’s
disease in her late 40s, and was documented to have low levels
of von Willebrand antigen of 0.36 IU (reference range
>0.50 IU), ristocetin cofactor activity of 0.30 IU (ref range
>0.50 IU), and a factor VIII level of 0.40 IU (Ref range 0.5-
1.5 IU). Around the same time, she was diagnosed with
moderate-to-severe obstructive sleep apnea-hypopnea.
Hepatic ultrasound revealed an enlarged liver with an
echotexture consistent with fatty infiltration, though she did
not report a history of high alcohol intake and denied tobacco
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smoking or the use of illicit drugs. In August of the year prior
to her consultation with us, her total cholesterol was
7.48 mmol/L (288.8 mg/dL), with LDL 5.4 mmol/L
(208.5 mg/dL), HDL 0.94 mmol/L (36.3 mg/dL) and triglyc-
erides 2.5 mmol/L (221.2 mg/dL) and her hemoglobin A1c
was elevated at 6.6 %. Healthy levels of lipids are total
cholesterol <5.2 mmol/L (i.e. <200.8 mg/dL), LDL
<3.4 mmol/L (i.e. <131.3 mg/dL), HDL >1.3 mmol/L (i.e.
>50.2 mg/dL) and triglycerides <1.7 mmol/L (i.e. 88.5 mg/
dL) (Genest et al. 2009). Repeat blood work done prior to her
clinic visit showed ApoB at 1.57 g/L (healthy range <1.25)
and hemoglobin A1c at 6.9 %. Taken together, her ApoB and
lipid levels were consistent with hyperlipidemia and her he-
moglobin A1c was in the range diagnostic for type 2 diabetes
(Miremadi et al. 2002;Wilson et al. 1998). At the time of these
tests, she was not taking any lipid or glucose-lowering drugs
because she had not found any that she was able to tolerate,
but she was taking ramipril 10 mg daily to lower her blood
pressure. She had tried many natural remedies in an effort to
alleviate her discomfort and had also experienced adverse
reactions to some of these remedies. She lives alone and does
not exercise regularly. Her medical problems had been
deemed significant enough to merit a disability pension.
Testing by Direct-to-Consumer Companies
Concerned in particular about her unusual series of adverse
drug reactions, and a history of health problems similar to her
own among several family members (Table I), she located a
private company that offered a “detoxigenomic panel” of SNP
polymorphism testing for drug metabolizing enzymes
expressed in the liver. The test reported that she might be
missing some of these enzymes, though the report was very
unclear; only generic recommendations were provided and the
section on “Physician Recommendations” for each SNP series
was left blank. The patient’s interest in genetic testing grew
and she became aware of 23andMe through a television series
on genealogy that featured a segment on genetics. By this time
she was, in her own words, “desperate for answers” for her
family. She initially had the company’s Personal Genome
Service SNP panel done, and later paid $999 US privately
for personal exome sequencing when 23andMe offered this to
its clientele as part of a research pilot project in late 2011
(“Exome 80x Pilot project” 27 Sept 2011). Four months after
she requested the test, the company provided her with the raw
data files (in .bam format).
The patient was aware that the company would not be
providing genetic counseling, but admitted that she did not
truly understand the results and their implications. Lacking the
appropriate software to open the .bam files, she contacted
various bioinformaticians through the internet, including her
local Genome Sciences Centre (Y.S. and S.J.), who agreed to
aid her in the interpretation of the data at no charge. That
bioinformatics team then identified a rare heterozygous vari-
ant in the CYP19A1 gene, which encodes aromatase, the rate-
limiting enzyme in the synthesis of estrogens fromC19 steroid
precursors. The variant is a c.358G >C variant in exon 4,
encoding the stop codon p.Tyr52X [genomic location
chr.15 g.51529196G>C (GRCh37/hg19 Assembly)].
Because this missense variant was predicted to result in a
truncation of the enzyme, and because haploinsufficiency for
the rate-limiting enzyme in estrogen synthesis might affect
circulating estrogen levels or local tissue concentrations of
estradiol, clinical correlation was sought in the context of the
patient’s medical and family history of polycystic ovarian
syndrome.
At that time, UBC’s clinical genetics unit had made an
informal policy decision to accept referrals for anyone docu-
mented to have carrier status for a rare genetic disorder,
whether ascertained DTC or clinically. A local clinical genet-
icist (W.T.G.) agreed to a session with the consultand to
provide genetic counseling for the rare variant found in aro-
matase, based on the information available at the time. Review
of the existing literature identified several individuals reported
to be affected with estrogen synthase deficiency, though de-
tails on clinically unaffected heterozygous carrier mothers
were too sparse to have real clinical utility. At that single
clinical visit, we decided that accurate genotype-phenotype
correlation would require Sanger sequencing confirmation of
the presence of the rare variant in CYP19A1, as well as family
studies, but that these could not be supported by publicly
funded healthcare. We offered to transition the woman’s
counseling to a “research-track” (managed by W.T.G. and S.
vdB, in consultationwith Y.S. and S.J.S. where necessary) and
to provide these additional tests under a research protocol at
no charge to her. She agreed to this plan in the knowledge that
the tests and counseling would be “research-grade” and not
“clinical-grade,” with the accompanying caveats (e.g. lack of
specific accreditation, unknown error rate, unknown turn-
around time, etc.). At the first (clinical) session, she also
requested that we provide counseling regarding common
CYP gene polymorphisms detected by the “detoxigenomic
panel” offered by the first DTC company she had contacted.
We declined this request because of the unknown analytical
validity and accuracy of the test results and confined our
counseling to the aromatase variant. Approximately 1 year
later, 23andMe provided the consultand with their own anal-
ysis of her exome, free of additional charge.
Clinical Assessment
The consultand’s personal history was as outlined above. On
exam, she had no dysmorphic features. Her weight was
80.9 kg and her height was 151.4 cm, for a calculated Body
Mass Index of 35.3 kg/m2.
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The three generation family tree, as reported by the
consultand, is presented in Fig. 1. Her parents are thought to be
remotely consanguineous; both are of Sinhalese descent from Sri
Lanka. Both are on lipid lowering and blood pressure medica-
tion. Overall, there is a family history of type 2 diabetes, myo-
cardial infarction, elevated serum cholesterol, skin cancer, hyper-
tension, menorrhagia and polycystic ovarian syndrome. Many
family members suffer from chronic pain, anxiety and depres-
sion. All of her family members have multiple ongoing health
complaints that significantly impact their daily functioning. The
consultand has investigated her ancestry on her own and through
SNP genotyping provided by 23andMe. She noted that many
distant relatives suffered from health problems similar to hers,
and often did not have children.
Sanger Validation of the Consultand’s Rare Variant
in Aromatase
Becausemany rare variants detected by next-generation sequenc-
ing methods are false-positives, best practice recommendations
are to verify the presence of such variants using an independent
method, such as traditional Sanger sequencing (Yang et al. 2013).
We designed our own in-house primers to validate the presence


















Fig. 1 CYP19A1mutation validation. The mutation was not found to co-segregate with the phenotype of Polycystic Ovarian Syndrome (black circles).
Unaffected individuals are represented by unfilled circles. The proband is indicated by the black arrow
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from the consultand, and to determine if a genotype-phenotype
correlation might be made by tracking the variant through family
members affected and unaffected by polycystic ovarian syn-
drome. All tested family members gave informed consent for
these sequencing studies. The variant was confirmed in the
consultand, but was not found to co-segregate perfectly with
the polycystic ovarian syndrome (PCOS) phenotype within the
family (Fig. 1).
ACMG Recommended Gene Analysis
When clinical-grade WES or whole-genome sequencing is
required for patients seen at British Columbia Children’s
Hospital or British Columbia Women’s Hospital, our clinical
unit currently outsources such testing to accredited clinical
labs outside the province, at significant cost to the public
health care system. One long-term goal of our center is to
offer clinical-grade WES and/or WGS “in-house,” which will
require the development of sufficient in-house expertise in
interpreting these data. Therefore, in addition to the workup
of the CYP19A1 variant, we attempted to follow the ACMG
Recommendations for reporting of incidental findings in clin-
ical exome and genome sequencing (Green et al. 2013) by
looking for rare variants in the 57 genes believed most likely
to harbor actionable mutations. Although these recommenda-
tions were not designed to apply specifically to research labs,
we decided it was best to attempt to follow these recommen-
dations because we wished to provide interpretation as close
to clinical-grade interpretation as was scientifically and eco-
nomically feasible. The consultand expressed interest in (and
gave consent to) being informed of any and all findings in
these 57 genes.
When analyzing this individual’s exome data for variants in
the genes recommended by ACMG, we found 50 variants in
26 of the 57 genes. These variants were subsequently checked
in dbSNP (build 138), 1000genomes, ClinVar and HGMD
professional (as of November 25, 2013). Fifteen of the vari-
ants were classifiable as being of unknown significance, 26
were predicted to be benign and 7 had mixed reports in terms
of their pathogenicity, with insufficient evidence to be clini-
cally actionable. Two variants were predicted to be damaging
and potentially clinically relevant. As recommended in the
guidelines, these were discussed with the consultand.
The LDLR gene, associated with familial hypercholester-
olemia (Fokkema et al. 2005), was found to have the
p.Glu250Lys variant, which was not found in dbSNP, 1000ge-
nomes or ClinVar, but was reported in the LDLR locus-
specific database and HGMD database (as of November 25,
2013). Yu et al. (2002) suggested this variant is pathogenic
based on its location in a crucial region within the protein, and
on its identification among members of a cohort ascertained
on the basis of familial hypercholesterolemia. However, no
functional experimentation has been published on this specific
variant. As we had done for the CYP19A1 variant, we vali-
dated the presence of the LDLR variant using in-house primers
and Sanger sequencing. We identified the variant in the pro-
band and in several of her family members, some of whom
had not yet had lipid levels measured. Even though we could
not definitively conclude that the familial LDLR variant was
causative of the proband’s hyperlipidemia, we offered
counseling to family members and recommended that the
consultand and all of her first-degree relatives consult with
their family physician(s) about having their fasting lipids
tested. We made this recommendation to all first-degree rela-
tives, whether or not we had identified the variant in their
DNA, because such screening was justified on the basis of the
clinical and family history alone. We considered this LDLR
variant to be a VUS according to the ACMG criteria, though if
the category “possibly pathogenic” (stronger evidence for
pathogenicity than a VUS but weaker than “probably patho-
genic”) were available we would consider it as such.
The APOB gene was identified to have a potentially path-
ogenic variant in our own analysis of the data, and was also
noted in the report provided to the consultand by 23andMe.
This variant (rs1042031) encodes a missense mutation, p.
Glu4181Lys. It is listed as having unknown significance in
dbSNP and was predicted to be benign by the 1000genomes
database. It was predicted by PolyPhen and SIFT to be benign.
HGMD associated the variant with ischemic stroke and aortic
stenosis in adults, and with increased APOB levels in the
Indian population. Other rare variants in the gene are thought
to cause familial hypercholesterolemia, although rs1042031
itself has not been proven to be a major Mendelian mutation
causative of familial hypercholesterolemia. We did not pursue
Sanger validation of this variant, because the incremental
benefit of DNA testing was believed to be minimal in light
of the ready availability of serum lipid levels as a screen for
hypercholesterolemia and hyperlipidemia, and the fact that we
had already counseled the consultand regarding familial hy-
perlipidemia. Like the LDLR variant, we considered this
APOB variant to be a VUS according to the ACMG criteria,
recognizing that it would be almost impossible to separate out
the allele-specific effect of the APOB variant from that of the
LDLR variant without a population-level sampling of other
individuals of similar ancestry and genotype on whom lipid
levels were available.
We also identified a rare variant in the VWF gene
(rs188526581), encoding a p.Asn1231Ser missense mutation.
Although not part of the ACMG recommended panel of
genes, we did discuss this variant with the consultand in light
of her known clinical diagnosis of vonWillebrand disease.We
did not pursue Sanger validation of this variant because we
believed that there would be no incremental value of such
testing for the consultand. She has no plans to reproduce, and
a clinically-validated test for circulating vWF levels is already
available to her first-degree relatives should they experience
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signs or symptoms of von Willebrand disease. We considered
this VWF variant to be “probably pathogenic” according to the
ACMG criteria.
Review of DTC Company Reports
When counseling the consultand, we relied primarily on the
analysis performed by the Genome Sciences Centre in
Vancouver (Y.S. and S.J.S.). We also examined the unofficial
reports, provided to us by the consultand, from two other
bioinformatics centers, as well as the “detoxigenomic” SNP
result that initiated the consultand’s interest in genetic testing.
Lacking detailed knowledge of 23andMe’s variant-calling
algorithms and other filtering protocols, we decided that we
would counsel based our own bioinformatics analysis of the
exome data and selected validation tests (Sanger sequencing
and clinical serum tests performed previously). 23andMe
provided the consultand with a report listing 37 selected
variants, a portion of which is shown in Table II. This com-
pany report noted the “predicted effect” of each variant, based
solely on the type of mutation (missense, nonsense, silent).
The consultand declined publication of the full 23andMe
variant report, because of the theoretical risk that such a profile
of rare variants might constitute a DNA fingerprint that could
be used by third parties to identify her unambiguously.
Summary of Genetic Counseling
With respect to the initial reason for consultation, we classified
the CYP19A1 variant as a VUS for polycystic ovarian syn-
drome and counseled the consultand that we could not be
certain whether this rare variant had any effect on her overall
health, on her unusual number of adverse reactions to medi-
cations, or on her polycystic ovarian syndrome. Based on
existing literature we considered it to be pathogenic for estro-
gen synthase deficiency, but since the consultand was hetero-
zygous we considered her to be a carrier of an autosomal
recessive disorder and not affected. The difference between
the reason for consultation (polycystic ovarian syndrome) and
the disease associated with the gene by other studies (autoso-
mal recessive estrogen synthase deficiency) illuminates an
emerging theme in the classification of rare variants: pathoge-
nicity (or lack thereof) may need to be defined in a disease-
specific way for genes that can be associated with multiple
phenotypes (e.g. APOE, LMNA, the androgen receptor, etc.).
The consultand was distressed for a brief time regarding the
implications of what she had read online regarding the phe-
notype of children born with estrogen synthase deficiency. We
reassured her that she was not at risk for this and that it would
be exceptionally rare for other branches of the family to be
affected unless they were to marry a blood relative.
With respect to the VWF variant, we considered her to be
affected with autosomal dominant von Willebrand disease.
We counseled her that the genetic testing explained why she
had this phenotype, but that it did not offer additional infor-
mation relative to her health status beyond what had already
been found via standard hematological assays. With respect to
the LDLR and APOB variants, we counseled her that one or
the other of these variants might explain her hyperlipidemia,
and that family studies were advisable. However, we specifi-
cally counseled her that these studies were advisable on the
basis of the lipid testing that she had already had and the
known risk to first-degree relatives of someone diagnosed
with hyperlipidemia. When she asked us to review the rare
variants reported by the company that we had not validated
ourselves (see Table II), we counseled her that this report was
of limited health value, because the company had only pro-
vided a list of “selected” variants without describing their
selection criteria. We counseled her that, on the basis of her
history and the limited physical examination that we had done,
many of these rare variants were clinically irrelevant. For
example, she had no cutaneous tumors or facial features of
trichorhinophalangeal syndrome, so the rare variants reported
in NF1 and TRPS1 were likely benign variants or possibly
false positives. When we pointed out the description “poly-
cystic kidney and hepatic disease 1 (autosomal recessive)”
associated with the PKHD1 variant, she said “that’s really
scary.” She rapidly began contextualizing the kidney and liver
disease within a genetic framework, leaping to the conclusion
that a change in this gene could be the cause.We reassured her
that even if this variant were present, at worst we would
interpret her clinical status as being an unaffected carrier of
an autosomal recessive disease. We said that we did not
believe her existing liver disease had anything to do with this
PKHD1 variant (and indeed, the hepatic ultrasound ordered
for other reasons prior to the DTC report had found fatty
infiltration but no cysts).
Clearly, not all of the rare variants flagged by the company
report were false positives, because the company report did
identify the VWF variant and the LDLR variant. The LDLR
variant was numbered using a different cDNA numbering
system than that used by the Genome Sciences Centre, which
again illustrates a difficulty that may present itself to clinicians
who undertake interpretation of DTC reports. The company
report did not identify the (now Sanger-validated) CYP19A1
variant, though it was clearly identifiable in our interpretation
of the company data provided to us by the consultand in .bam
format.
Discussion
We were consulted by a woman who had undergone Whole
Exome Sequencing (WES) from a direct-to-consumer (DTC)
company, and who was willing to share with us the data and
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reports provided by the company so that we could offer
something approximating clinical recommendations based
on these results. This situation provided us with a unique
opportunity in genetic counseling, as it mimicked a scenario
frequently discussed as a hypothetical: an individual who
seeks medical and/or genetic advice regarding the
actionability of a DTC company’s reports. This situation also
provided us with a unique challenge: that of meeting our
fiduciary duty to the consultand at a time when such duties
have yet to be defined rigorously. Indeed, our perception of
our own fiduciary duties shifted during the time of the project
itself – from a very limited duty to interpret the medical
consequences of the rare variant in CYP19A1 to a broader
duty to search her variant file for rare variants in the ACMG’s
list of actionable genes once their position statement was
published (Green et al. 2013). In an attempt to avoid incurring
additional costs to our province’s publicly-funded health care
system, we avoided repeating tests that had already been
performed clinically (i.e. vWF levels and lipid levels).
We made it clear from the beginning that our involvement
was for the validation of the CYP19A1 mutation and that we
did not have the resources to validate every rare variant
identified by our own analysis or that of the DTC company.
To Sanger-validate each of these would take many hours
(Ormond et al. 2010) and the design of multiple primer sets.
Although we did not specifically review each individual var-
iant with the consultand, we explained the evaluative process
on which we determine whether a variant is pathogenic from
primary literature. After a thorough search of the literature on
CYP19A1, we ultimately concluded that the best interpretation
of her CYP19A1 result was that she was a carrier of autosomal
recessive aromatase deficiency. There are limited data in the
literature on the phenotypes of mothers of children affected
with autosomal recessive aromatase deficiency, and no spe-
cific mention was made regarding whether any had manifest-
ed irregular menses, partial estrogen deficiency or polycystic
ovarian syndrome. As a result, we were not able to reach a
definitive conclusion on the pathogenicity of rare variants in
CYP19A1 for polycystic ovarian syndrome. Though it is intu-
itively appealing that truncating mutations in an enzyme such
as this one would be a rare but major risk factor for a common
disease like polycystic ovarian syndrome (Deladoey et al.
1999; Lafranco et al. 2008; Lin et al. 2007; Pepe et al. 2007;
Zirilli et al. 2008), it is important that exome sequencing
results (especially DTC exome sequencing results) not be
over-interpreted on the basis of intuitive appeal.
The variant reported provided to the consultand by
23andMe provided details on 37 variants selected out of the
many thousands that were identifiable in the .bam file. The
report on rare variants provided by 23andMe to the consultand
listed the location and nature of the rare variants, but provided
no interpretation regarding their pathogenicity. Instead, it used
a very rudimentary classification system that binned variants
into those having “mild,” “moderate” and “high” impact. The
company’s research report did include the explicit disclaimer
that it was not comprehensive and was provided “for infor-
mation purposes only,” though the language used elsewhere in
the results could easily have been confused with a report that
was intended to identify disease-causing alleles. For example,
a rare variant in PKHD1was reported as occurring in the gene
for “polycystic kidney and hepatic disease 1 (autosomal re-
cessive).” The Exome 80X Pilot program was a research pilot
advertised as “suitable for customers who are comfortable
managing and understanding raw genetic data” (“Exome
80x Pilot project”, 27Sept2011), so it is not surprising that
the report was not curated to the extent that would be expected
of a clinical exome. Nonetheless, a printed report of this nature
carries a risk of eliciting anxiety in the mind of a recipient who
is not intimately familiar with the analysis of genomic data (as
this consultand was not) (Egglestone et al. 2013). For exam-
ple, the mention of polycystic kidney and hepatic disease 1
(autosomal recessive) caused the consultand to become con-
cerned, considering the context of her family’s history of
kidney and liver disease as well as her own (see Table I).
The company report also flagged rare heterozygous vari-
ants in NF1 and TRPS1, which would, if truly present and
functional, cause autosomal dominant disorders (neurofibro-
matosis (OMIM #162200) and trichorhinophalangeal syn-
drome (OMIM # 190350), respectively). However, it was
clear from her medical history and physical exam that neither
disorder was present.
Review of various online databases (including locus-
specific databases) may provide some indication of a variant’s
pathogenicity, but it is also important to consider the
consultand’s ancestral or ethnic group. A common method
of assessing pathogenicity is the presence of the variant of
interest in affected consultands and its absence from healthy
individuals (MacArthur et al. 2014). However, a rare benign
variant may be inaccurately classified as pathogenic if one
assumes that its low prevalence is indicative of pathogenicity
(Ackerman et al. 2003). As was counseled in the case report
by Sturm and Manickam (2012), pathogenicity of a variant
cannot be assumed if the ethnic group in which a variant is
reported as pathogenic is different from that of the consultand.
As no current Sinhalese reference genome exists, we encoun-
tered an additional challenge in interpreting our consultand’s
variants.
The consultand initially approached us with a strong belief
that the cause of her health problems could be found within
her genome. She fit some aspects of the description of an
“early adopter” (McBride et al. 2009), but not others. She had
no university-level science courses in her educational history
and did not have a high level of prior genetic knowledge
(although she was eager to learn about and to discuss her
results). Additionally, while early adopters are typically more
interested in their future susceptibility to common disease, our
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consultand was looking for genetic causes for her current
medical problems, and for those affecting her immediate
family members. Despite our caution that genetic causes for
common, complex disease are unlikely to be found within her
genome, the consultand strongly attributed her multiple health
issues to a genetic cause. She attributes her history of unusual
reactions to medications to genetic variants in CYP450 en-
zymes; this attribution had been strengthened by previous
DTC testing of polymorphisms in CYP450 enzymes.
When examining the ACMG’s list of genes, we found two
rare variants (in LDLR and APOB) as well as one inVWF to be
potentially pathogenic in the heterozygous state. The
consultand’s personal history of von Willebrand disease and
her personal and family history of hyperlipidemia did assist us
in making actionable recommendations, though a specific
causal relationship between these variants and the conditions
could not be established without functional studies that would
have required site-directed mutagenesis, subcloning and cell
culture work. Although we did recommend screening for von
Willebrand disease and hyperlipidemia among her first-degree
relatives, such family screening was already advisable on the
basis of her own prior history of low plasma von Willebrand
factor and elevated plasma lipids. The fact that our recom-
mendations were made primarily on the basis of existing
clinical diagnoses calls into question the cost-effectiveness
and incremental benefit of WES in cases similar to hers
(Dorschner et al. 2013).
The boundaries of the fiduciary duty for counseling
consultands on DTC company genetic testing results (panel
or whole exome sequencing) are unclear. Our team had direct
access to sophisticated bioinformatics and to Sanger sequenc-
ing in a research setting, tools which are not commonly
available to family physicians or to genetic counselors in the
community. Such sessions need to be educational for the
consultand so that they leave the session equipped to do
independent additional and future interpretation (Sturm and
Manickam 2012). Although requests to interpret a SNP panel
are more common thanWES (and involve fewer variants than
WES), these requests will still take a considerable amount of
time and bioinformatic expertise.
Conclusion and Lessons Learned
From the very beginning, we entered into a therapeutic con-
tract with the consultand where we were clear and specific on
what we could provide in terms of interpretation. For example,
we declined to interpret pharmacogenetic variants that might
influence the metabolism of flutamide, since specific well-
accepted data are lacking in the primary literature to justify
this sort of genotype-phenotype correlation. We also declined
to interpret every variant in the context of every disease
present in the family because disentangling the individual
contributions of each variant to common, complex diseases
such as type 2 diabetes, depression and fatty liver is currently
impossible. We focused instead on answering clearly-
predefined questions regarding the potential contribution of
the CYP19A1 variant to polycystic ovarian disease (through
genotype-phenotype correlations). When the new ACMG
guidelines were published, we recontacted the consultand
and updated our therapeutic contract and informed consent
to include Mendelian variants potentially causative of other-
wise undiagnosed adult-onset disease.
Requests by consultands for interpretation of DTC compa-
ny genetic testing are still infrequent. We caution health care
professionals regarding reports provided by labs that are not
certified for medical testing, because consultands will likely
expect that any relevant information that is not included in the
report itself will be supplied by the interpreting counselor or
physician (Howard and Borry 2013). Supplying this informa-
tion is a time-consuming process, requiring an average of 23–
54 min per variant for a trained genetics professional (Dewey
et al. 2014; Yang et al. 2013), exclusive of any validation
studies that may be required.
It must be borne in mind that individuals who request
interpretation of a DTC exome or other DTC test are very
likely to have a pre-existing belief that significant, actionable
answers will be found in their genomic results. If they did not
hold such a belief, it is unlikely that they would have paid for
the test in the first place. We believe that public dissemination
of successes in identification of genes for rare Mendelian
diseases has enhanced expectations in the minds of many
members of the public that DNA testing can find “the gene
for” their disease. Repeated uses of the phrase “the gene for”
in multiple media reports may have led them to expect that
genetic contributors to common diseases are identifiable using
means similar to those used for rare Mendelian diseases. The
mismatch between the expectations of a consultand and what
actionable results a health-care provider can feasibly extract
from a SNP profile or an exome may lead to frequent disap-
pointment in the DTC genetic testing setting. We would
advise genetic counselors to be very cautious in accepting
requests to examine DTC data, due to the volume of results
and the large amount of work that is required to be certain of
the accuracy of each result. For example, the sheer number of
variants identified in an exome precludes independent Sanger
validation of each rare or common variant.
Throughout this article, we have used the term
“consultand” rather than “patient,” in order to make a distinc-
tion between individuals who seek interpretation for
medically-certified tests (i.e. patients) and individuals who
seek interpretation for the results of uncertified tests (i.e.
consultands). The latter situation is not a medical process
(though it looks very much like it) and such consultations
should take place outside of publicly-funded health care sys-
tems, such as in a research setting or a private-pay scenario.
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Our experience with this case convinces us that such
consultations are not cost-effective within a publicly
funded health-care system, particularly if independent clin-
ical Sanger validation would be required for every variant.
Worthy of note is the fact that the DTC exome report
provided by the company to the proband was explicitly
labeled “for information purposes only.” However, we
believe that interpretation of rare variants within the ex-
ome is intrinsically a medical testing process. The fact that
the company report included mention of polycystic kidney and
hepatic disease (our italics) and of medical terms like neurofi-
bromatosis and trichorhinophalangeal syndrome means it cannot
be considered to contain information that is strictly non-medical
in nature.
The US Food and Drug Administration (FDA) has recently
issued a warning letter to 23andMe regarding their direct-to-
consumer genetic testing, ordering the company to cease
marketing the aspects of their SNP genotyping that could be
confused with medical testing by members of the public
(Gutierrez 2013). This move by the FDA is applauded by
some (Annas and Elias 2014) and deemed too harsh by others
(Green and Farahany 2014). 23andMe has complied with this
order (Gutierrez 2014) and had not, to our knowledge, ever
marketed DTC exomes outside of their time-limited Exome
80X Pilot Programwhich was closed to enrollment prior to the
FDA warning. Because of the potential for confusion with
medical testing, we regard the reporting of rare variants in
OMIM genes (i.e. genes confidently known to be associated
with Mendelian disease) as being intrinsically a medical pro-
cess, one that should be conducted only through the auspices
of a medically certified lab or a research study approved by an
independent research ethics board. Should private companies
like 23andMe seek to enter the DTC exome space, we believe
it is most advisable that they seek first clinical certification,
engage experienced bioinformaticians, molecular geneticists,
clinical geneticists and genetic counselors on their staff, and
issue reports that incorporate detailed interpretation of the
pathogenicity (or lack thereof) of the rare variants they
identify.
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